Skip to main content

What the FDA labels say about taking them together

Digoxin and lenalidomide

Lenalidomide's FDA label of March 24, 2023 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name lenalidomide. The lenalidomide label: “Monitor digoxin plasma levels periodically due to increased C max and AUC with concomitant REVLIMID therapy.”

Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the lenalidomide FDA label on DailyMed (effective March 24, 2023, Celgene Corporation).

What does the digoxin label say about lenalidomide?

Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name lenalidomide in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed

What does the lenalidomide label say about digoxin?

Lenalidomide label, drug interactions

Monitor digoxin plasma levels periodically due to increased C max and AUC with concomitant REVLIMID therapy ( 7.1 ).

Source: FDA drug label (Revlimid), NDA021880 (Bristol Myers Squibb), as published by Celgene Corporation, effective March 24, 2023 (SPL set 5fa97bf5-28a2-48f1-8955-f56012d296be), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

26Digoxin generic labelers
18Lenalidomide generic labelers
DigoxinLenalidomide
Labeled forHeart failure, Atrial fibrillationLeukemia, lymphoma and myeloma, Anemia
Boxed warningNoYes
Pharmacy cost (NADAC)$0.133 per tablet 125 mcg tabletn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?